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SARS-CoV-2 infection and neuropsychological outcomes
Abstract. The entire world is currently confronted with the Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2), a novel betacoronavi‑
rus causing the deadly pandemic of coronavirus disease 2019 (COVID‑19). 
Since there is now increasing reports of neurological and cognitive problems, 
the impact of COVID‑19 on neuropsychological functioning is unknown 
but is likely to leave residual problems.
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Introduction. The last pandemic was documented about a centu‑
ry ago (1918). Following that pandemic, Parkinson’s Disease emerged 
as a major neurological disease that posed significant neurological and 
neuropsychological morbidity until the discovery of first‑ generation 
anti‑ Parkinsonian medication in the late 1940’s, providing management 
of the disease. In the current pandemic, patients with comorbid health 
problems of all ages are at risk for serious health problems or sadly, have 
succumbed to COVID‑19. Isolated case studies of pregnant women such 
as that of Hosier et al. [1] recently reported two cases suggesting that 
the SARS‑CoV‑2 virus may cross the placental barrier, infecting the fetus. 
IN Texas’ Nucces County in the USA, 85 infants under the age of 1 year 
have tested positive for the novel coronavirus. In adults in particular, 
the impact of the virus has been varied with acute changes in breathing 
and hypoxia to blood clots and strokes, and microbleeds [2], in many 
instances, requiring ICU management and ventilation. The delayed ef‑
fects of COVID‑19 on neuropsychological functioning are unknown. 
Although the significant death‑rate worldwide has triggered alarm and 
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anxiety as well as fear of impending death particularly in the absence 
of a vaccine, psychological distress and other cerebral effects are reported. 
The impact on cerebral functioning is anticipated in view of two possible 
effects. Since SARS‑CoV‑2 uses the angiotensin converting enzyme 2 
(ACE2) receptor [3] as an access portal to the lungs, the indirect effects 
of low blood oxygen saturation levels or hypoxia may on cerebral func‑
tioning is unknown. On the other hand, ACE2 and its receptors are also 
found in the brain especially in CNS neurons and glial cells thus making 
it a potential target for possible direct infiltration by SARS‑CoV‑2 virus. 
Individuals infected with SARS‑CoV‑2 virus have complained of loss 
of taste and smell with infection of the olfactory bulb suspected to be 
pathway of entry into the cerebral structures. Since the medical manage‑
ment of COVID‑19 is improving with ventilation, corticosteroids and 
other supportive measures, a large proportion of these patients is expect‑
ed to recover from the disease. For patients who recover, the possibility 
of lingering cognitive and behavioural effects are unknown although they 
are likely to be present. Therefore, the post‑acute and long‑term effects 
of COVID‑19 on the cognitive and behavioural functioning of individ‑
uals are expected to constitute an important area of neuropsychological 
research and clinical practice in coming months and years.
Materials and Methods. As cases of COVID‑19 increase, and with 
decreasing medical management burden in the post‑acute and chronic 
phase of treatment, patients will likely form a large pool of surviving 
cases that require neuropsychological assessment and treatment and 
possibly, long‑term rehabilitation. These interventions will be dependent 
on individual recovery outcomes from the disease. Hence, using Luria’s 
Neuropsychological Assessment methods [4] and those using this frame‑
work [5] forms an appropriate serial monitoring method of cognitive 
and behavioural progress after COVID‑19 infection. Therefore, forming 
a case series of COVID‑19 patients from various medical clinics (using 
multisite protocols) is an appropriate clinical research protocol that should 
be urgently initiated.
Results. The investigation of individual cases of patients who recovered 
from COVID‑19 should be analyzed individually to portray the socio‑ 
cultural impacts of the disease and, from a group perspective, general 
trends of cognitive and behavioural trajectories post‑recovery may be 
tracked.
Conclusions. Using Luria’s Syndrome Analysis [4, 5] to study the neu‑
ropsychological profiles of individual COVID‑19 patients, ranging in age 
from infancy to late adulthood, affords a unique opportunity to track 
the neuropsychological changes of patients recovering from the disease, 
identify areas of the brain that are susceptible to hypoxic brain damage, 
predict their outcomes and contribute to the development of future neu‑
ropsychological rehabilitation and medical control of long‑term sequelae 
of future viral pandemics impacting the brain.
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